Stage IV Cancer Statistics in US 2026 | Key Facts

Stage IV Cancer in America 2026

Stage IV cancer — also called metastatic cancer or distant-stage cancer — is the most advanced classification in the cancer staging system used across the United States. At this stage, the original tumor has spread beyond its primary site to distant organs, lymph nodes, or tissues elsewhere in the body. Whether it is a stage IV lung cancer diagnosis that has traveled to the brain, a stage IV breast cancer case that has reached the liver and bones, or stage IV pancreatic cancer that has seeded the surrounding organs, the defining feature is always the same: the disease is no longer localized. In 2026, according to the American Cancer Society’s Cancer Facts & Figures 2026 — compiled using data from the National Cancer Institute’s (NCI) Surveillance, Epidemiology, and End Results (SEER) Program — an estimated 2,114,850 new cancer cases will be diagnosed across the United States. Of those, a substantial proportion will present at the distant or advanced stage, making stage IV cancer in America 2026 one of the most pressing oncology challenges facing the healthcare system today.

What makes the stage IV cancer picture in the US both alarming and, in some ways, encouraging in 2026 is the complexity of the trends. On one hand, overall cancer mortality has declined continuously since 1991, averting an estimated 4.8 million cancer deaths through 2023, according to the January 2026 publication in CA: A Cancer Journal for Clinicians. On the other hand, survival rates for distant-stage (stage IV) cancer remain dramatically lower than for localized or regional disease. The 5-year relative survival rate for all distant-stage cancers stood at just 35% for diagnoses during 2015–2021, compared to 69% for regional-stage disease and nearly 100% for localized cancers in several types. These numbers — tracked meticulously by the NCI’s SEER Program and the CDC’s National Program of Cancer Registries (NPCR) — reveal that while medicine is advancing, catching cancer before stage IV remains, without question, the most powerful tool available.

Key Interesting Facts About Stage IV Cancer in the US 2026

Before diving into the detailed statistics sections, here are the most striking facts and figures about stage IV cancer in the US 2026 that everyone should know. These facts come directly from the NCI SEER Program, the American Cancer Society’s Cancer Facts & Figures 2026, and the CDC.

Data Source: American Cancer Society. Cancer Facts & Figures 2026. Atlanta: American Cancer Society; 2026. Siegel RL, et al. Cancer statistics, 2026. CA Cancer J Clin. 2026;76(1):e70043. National Cancer Institute SEER Program, seer.cancer.gov.

The table above paints a picture that is equal parts sobering and remarkable. The 3% five-year survival rate for stage IV pancreatic cancer and the roughly 10% rate for distant-stage lung cancer underscore how critical early detection remains, while the extraordinary improvement in stage IV melanoma survival — from 16% to 35% in just over a decade — shows what targeted research investment can achieve. The fact that lung cancer in 2026 will kill more Americans than colorectal and pancreatic cancer combined — despite its mortality rate trending downward — speaks to the sheer scale of the metastatic cancer burden in the United States.

These milestones represent more than statistical improvements — they reflect decades of sustained federal investment in cancer research, improved systemic therapies including immunotherapy and targeted agents, and expanded early detection programs. Yet the fact that the overall distant-stage 5-year survival is still only 35% shows that the gap between localized and advanced cancer outcomes remains enormous, and closing that gap is the defining mission of oncology in 2026.

Stage IV Cancer Incidence and Mortality in the US 2026

Understanding how many Americans are diagnosed with and killed by stage IV cancer in the US 2026 is the first step in grasping the full scope of this public health challenge.

Data Source: Siegel RL, et al. Cancer statistics, 2026. CA Cancer J Clin. 2026 Jan 13;76(1):e70043. Published by Wiley on behalf of the American Cancer Society. Data derived from NCI SEER Program and CDC NPCR, incidence through 2022, mortality through 2023.

The numbers in this table are staggering in their scale. Lung and bronchus cancer alone accounts for an estimated 124,990 deaths in 2026, a figure larger than the projected combined death toll from colorectal cancer (55,230) and pancreatic cancer (52,740). The overwhelming majority of lung cancer deaths occur in patients who were diagnosed at an advanced stage — with approximately 57.4% of lung cancer cases first diagnosed at the distant (stage IV) stage, according to the NCI SEER data. That means well over 100,000 Americans confronting a lung cancer diagnosis each year are already at stage IV when cancer is first found.

Pancreatic cancer presents an equally grim picture when examined through the lens of stage at diagnosis. The cancer is notorious for being asymptomatic in its early stages, which means the vast majority of its 68,180 estimated new cases in 2026 will be diagnosed at regional or distant stage. With a 3% five-year survival for distant-stage pancreatic cancer, it remains among the hardest cancers to treat once it reaches stage IV. The broader point these numbers drive home is that cancers with the highest mortality ratios — the ratio of deaths to new cases — are consistently those where stage IV diagnoses dominate. Liver cancer, with 43,360 new cases and 32,010 deaths, has a mortality ratio that reflects how commonly it is caught late.

5-Year Survival Rates for Stage IV (Distant-Stage) Cancer in the US 2026

Survival statistics are the clearest lens through which to understand the severity of stage IV cancer in the US compared to earlier-stage diagnoses. The following table presents the 5-year relative survival rates for distant-stage cancer — the SEER equivalent of stage IV — for the most common cancer types, based on cases diagnosed between 2015 and 2021 and followed through 2021.

Data Source: NCI SEER Program. SEERExplorer, seer.cancer.gov. American Cancer Society. Cancer Facts & Figures 2026. Atlanta: ACS; 2026. Siegel RL et al., CA Cancer J Clin. 2026;76(1):e70043. Survival data based on SEER 21 registries, diagnoses 2015–2021.*

The contrast between localized and distant-stage survival is perhaps nowhere more stark than in pancreatic cancer. A patient diagnosed at the localized stage has roughly a 44% chance of surviving five years — not great, but survivable in nearly half of cases. A patient diagnosed at stage IV (distant) pancreatic cancer faces a devastating 3% five-year survival rate. That is not a typo: 97 out of every 100 people diagnosed with stage IV pancreatic cancer will not survive five years. The numbers for small cell lung cancer (SCLC) at distant stage are almost as grim, at just 4%. Together, these figures make the scientific imperative for earlier detection unmistakable.

What gives researchers and patients reason for cautious optimism is the trajectory of improvement. Metastatic melanoma’s 5-year survival rate has leapt from just 16% in 2009 to 35% in 2014–2020, driven almost entirely by immunotherapy breakthroughs — specifically checkpoint inhibitors like pembrolizumab and nivolumab. Myeloma’s distant-stage survival has nearly doubled, from 32% to 62%, since the mid-1990s, thanks to novel drug classes including proteasome inhibitors and immunomodulatory agents. Liver cancer’s survival at distant stage rose from 7% to 22% over the same period — a tripling that reflects newer targeted therapies. These improvements validate the power of sustained research investment and show that even stage IV cancer statistics are not fixed numbers, but live outcomes that respond to scientific progress.

Stage IV Cancer Survival Improvements Over Time in the US 2026

One of the most compelling dimensions of the 2026 stage IV cancer statistics in the US is the historical trajectory of survival gains. The NCI SEER data allows us to compare contemporary distant-stage survival rates to those from the mid-1990s, revealing where the most dramatic progress has been made.

Data Source: Siegel RL, et al. Cancer statistics, 2026. CA Cancer J Clin. 2026 Jan 13;76(1):e70043. PMC12798275. National Cancer Institute SEER Program; American Cancer Society Cancer Facts & Figures 2026.

The headline number from this table is the doubling of overall distant-stage survival, from 17% in the mid-1990s to 35% today. That improvement represents hundreds of thousands of Americans who are alive today because of advances in how stage IV cancer is treated. The +30 percentage point gain for metastatic myeloma is arguably the most transformative story in modern oncology — a cancer that was once nearly always fatal within a few years of a distant-stage diagnosis is now being managed as a more chronic condition, with a majority of patients surviving past five years. The rise in metastatic liver cancer survival from 7% to 22% — a tripling of the rate — reflects the impact of newer targeted therapies like sorafenib and atezolizumab-bevacizumab combinations.

Looking at these survival improvements alongside the still-modest absolute rates is the right way to contextualize the 2026 data. Metastatic lung cancer survival improving from ~2% to ~10% is a five-fold increase — impressive in relative terms, and yet in absolute terms, 9 out of 10 patients with stage IV lung cancer still do not reach the five-year mark. The 10-percentage-point gain in metastatic rectal cancer survival, from 8% to 18%, is genuinely meaningful for patients — but an 18% five-year survival rate at stage IV still means the vast majority of those patients face a terminal prognosis. These juxtapositions are not meant to diminish the science. They are meant to show, plainly, why the fight against late-stage cancer in America is far from over.

Stage IV Cancer by Type — Incidence at Distant Stage in the US 2026

Not all cancers carry the same likelihood of being diagnosed at stage IV. The following table presents data on the percentage of cases diagnosed at distant (stage IV) stage for the most common cancer types in the United States, based on the most recent NCI SEER data.

Data Source: NCI SEER Cancer Stat Facts, seer.cancer.gov/statfacts. NCI SEERExplorer. American Cancer Society. Cancer Facts & Figures 2026. Atlanta: ACS; 2026. Stage distribution data from SEER 21 registries, 2015–2021.*

The percentages in this table reveal a deeply uncomfortable pattern: the cancers with the worst survival outcomes at stage IV are also the ones most likely to be found at that advanced stage in the first place. Lung cancer and ovarian cancer each see approximately 57% of diagnoses occur at the distant stage, meaning more than half of all new patients with these cancers are facing a stage IV prognosis from the very beginning. Pancreatic cancer — the one with the lowest stage IV survival rate in the US at just 3% — is diagnosed at distant stage in over half of all cases. These are not coincidences. These are cancers that are typically asymptomatic until well advanced, with few reliable screening tools compared to breast, colorectal, or prostate cancer.

By contrast, melanoma — which has seen the most dramatic survival improvements at stage IV — is diagnosed at a distant stage in only about 4% of cases, thanks in part to the visibility of skin lesions and relatively widespread awareness about skin checks. Breast cancer is diagnosed at distant stage in just ~6% of cases, a testament to the power of mammography screening programs. Prostate cancer’s distant-stage diagnosis rate of ~8% similarly reflects the widespread use of PSA testing. These comparisons make the case that cancer screening programs directly reduce stage IV cancer rates — and that expanding access to those programs, particularly for lung, ovarian, and pancreatic cancers, is among the most impactful interventions available in 2026.

Stage IV Cancer Racial and Geographic Disparities in the US 2026

Stage IV cancer statistics in America do not fall evenly across the population. Race, ethnicity, geography, and socioeconomic status all meaningfully affect who gets diagnosed late and who survives.

Data Source: ACS Cancer Facts & Figures 2026; Siegel RL et al., CA Cancer J Clin. 2026;76(1):e70043; NCI SEERExplorer accessed 2025; ACS Cancer Statistics for Black People, 2025, CA Cancer J Clin; Trilliant Health Analysis of ACS 2026 Report, February 2026.*

The racial disparities embedded in these stage IV cancer statistics are among the most troubling findings in the 2026 data. Black women with uterine corpus cancer face a 5-year survival rate of just 63% compared to 84% for White women — a gap driven by later stage at diagnosis, more aggressive tumor subtypes, and documented disparities in access to guideline-concordant treatment. Black women are 40–70% more likely than non-Hispanic White women to be diagnosed at stage IV breast cancer across all four major subtypes, according to a SEER-based analysis published by the AACR. When more than half of Black women in the US receive a breast cancer diagnosis at a more advanced stage, and when the stage IV breast cancer 5-year survival is just 33% versus 100% for localized disease, the compounding effect is a mortality gap that is not explained by biology alone.

The geographic data adds another dimension to this picture. Kentucky leads all US states with the highest estimated cancer incidence rate of 528.3 per 100,000 in 2026, while New Mexico sits at the opposite end at 388.0 per 100,000 — a difference of over 140 cases per 100,000. Rural communities consistently show higher rates of later-stage diagnosis across lung, breast, pancreatic, and cervical cancers compared to urban populations, reflecting differential access to screening programs, specialist care, and early detection infrastructure. The ACS has explicitly attributed these rural-urban disparities to higher rates of obesity, heavy alcohol use, physical inactivity, and lower adherence to recommended cancer screenings in rural areas. Addressing these disparities — in both race and geography — is inseparable from the mission of reducing stage IV cancer mortality in the US over the next decade.

Stage IV Cancer Survival Improvement by Therapy Type in the US 2026

Modern oncology has unlocked extraordinary gains in metastatic cancer survival through new treatment modalities. The following table captures the impact of specific therapeutic advances on stage IV cancer outcomes in the US.

Data Source: Siegel RL et al., CA Cancer J Clin. 2026;76(1):e70043. PMC12798275 (NCI/PMC); ACS Cancer Treatment & Survivorship Statistics 2025, PMC12223361; Chopra D et al., Real-World Treatment Patterns, Metastatic NSCLC, Curr Oncol. 2025;32:151.

The therapeutic progress captured in this table represents what decades of NCI-funded research can produce. The story of metastatic melanoma is perhaps the most dramatic: a cancer that was almost universally fatal within 12–18 months of a stage IV diagnosis in 2009 now carries a 35% five-year survival rate, driven almost entirely by a new class of drugs — immune checkpoint inhibitors — that teach the body’s own immune system to recognize and attack cancer cells. The myeloma story is equally remarkable: the introduction of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies has pushed stage IV myeloma survival from 32% to 62% — nearly doubling the rate in roughly 25 years. For stage IV lung cancer (NSCLC), the shift is from an era where essentially no patients survived five years to one where approximately 1 in 10 does — and for the subset with actionable driver mutations treated with targeted therapies, outcomes are considerably better.

Real-world data from a 2025 study of 15,659 patients with metastatic NSCLC treated between 2020 and 2023 found that 47% received immune checkpoint inhibitor (ICI) plus platinum-based chemotherapy as their first-line treatment, reflecting how rapidly the oncology standard of care has evolved. CDK4/6 inhibitors — drugs like palbociclib, ribociclib, and abemaciclib — have fundamentally changed the management of HR-positive, HER2-negative metastatic breast cancer, enabling many patients to manage their stage IV diagnosis as a chronic illness with substantially extended progression-free survival. These are not small incremental gains. They are paradigm shifts, and they demonstrate what is achievable when research investment is sustained.

Stage IV Cancer Economic Burden in the US 2026

The financial cost of stage IV cancer in the US in 2026 is staggering, placing enormous pressure on patients, families, insurers, and the federal healthcare system alike.

Data Source: NCI Cancer Trends Progress Report — Financial Burden of Cancer Care, progressreport.cancer.gov; NIH/NCI Annual Report to the Nation Part 2, JNCI 2021; Siegel RL et al., CA Cancer J Clin. 2026; NCI Budget page, cancer.gov/about-nci/budget.

The economic data around stage IV cancer in the US reveals a crisis within a crisis. End-of-life phase care — which disproportionately involves patients with metastatic or stage IV cancer — carries an average annualized medical cost of approximately $105,500 per patient, according to NCI-linked research. When multiplied across the hundreds of thousands of Americans dying from stage IV cancer each year, this generates healthcare expenditures that are simply unsustainable on current trajectories. Overall national cancer care costs were $190.2 billion in 2015 and are projected to reach approximately $246 billion by 2030 based on demographic growth alone — meaning even without any increase in cancer incidence rates or treatment costs per patient, the system faces a massive spending surge simply because the US population is aging and growing.

What makes this particularly urgent in 2026 is the policy environment. The NCI received a $7.35 billion Congressional appropriation for FY2026, a modest increase from FY2025. However, proposed executive budget cuts — which would have slashed NCI funding by approximately 37% — were only reversed through legislative action. The ACS Cancer Action Network has documented that NCI-supported clinical trials between 1980 and 2020 added 14.2 million additional life-years to cancer patients in the United States. Cutting the research infrastructure that produced those gains would not just slow scientific progress — it would directly translate into more Americans being diagnosed at stage IV rather than stage I or II, and more Americans dying from cancers that were, in earlier patients, survivable. The financial and human cost of that outcome would dwarf any short-term budget savings.

Disclaimer: The data reports published on The Global Files are sourced from publicly available materials considered reliable. While efforts are made to ensure accuracy, no guarantees are provided regarding completeness or reliability. The Global Files is not liable for any errors, omissions, or damages resulting from the use of these reports.